Monoclonal antibody · Inhibitor of B-lymphocyte stimulator (BLyS) (TNFSF13B) · developed by Human Genome Sciences
Belimumab is a fully human monoclonal antibody that binds soluble B-lymphocyte stimulator (BLyS), blocking its binding to receptors on B cells. This reduces B-cell survival and their differentiation into immunoglobulin-producing plasma cells. It is used in systemic lupus erythematosus and lupus nephritis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 21, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01632241 | Phase 4 | Systemic Lupus Erythematosus | Completed | GSK |
| NCT00712933 | Phase 3 | Systemic Lupus Erythematosus | Completed | GSK |
| NCT01649765 | Phase 2 | Systemic Lupus Erythematosus | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Systemic Lupus Erythematosus
Updated Oct 18, 2026.